Drug Profile


Alternative Names: MVA-BN RSV; MVA-mBN294B; Respiratory syncytial virus vaccine - Bavarian Nordic

Latest Information Update: 11 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bavarian Nordic
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 09 Nov 2017 Bavarian Nordic initiates a phase II extension booster trial for Respiratory syncytial virus infections in USA
  • 08 Nov 2017 Bavarian Nordic plans a end of phase II meeting with the US FDA to determine registration pathway for MVA-BN RSV in elderly patients in the second half of 2018
  • 21 Sep 2017 Bavarian Nordic plans a human challenge study for Respiratory syncytial virus infections (In volunteers, Prevention) in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top